| アブストラクト | BACKGROUND: The triglyceride-lowering drug, icosapent ethyl (IPE), was granted a new indication for the reduction of atherosclerotic cardiovascular disease risk in 2019. This study aimed to investigate the safety profile of IPE by mining the FDA Adverse Event Reporting System (FAERS) database. METHODS: The reporting odds ratio was used to analyze IPE's adverse events (AEs) based on the FAERS data from July 2012 to December 2022. We described the characteristics of AE reports and evaluated the clinical prioritization of AEs. Then we defined and analyzed nine interested adverse drug reactions (ADRs) in both overall and subgroups, and investigated the times to onset. RESULTS: The findings of our study strengthen the evidence for an increased risk of atrial fibrillation using IPE. IPE alone may not increase the risk of bleeding unless combined with antithrombotic drugs. Similar to statins, IPE alone can increase the risk of musculoskeletal pain, drug-related hepatic disorders, and hyperglycemia, but the risk could not double when IPE was combined with statins. Most ADRs occur in the early stage of treatment. CONCLUSIONS: This study provides a comprehensive real-world safety profile of IPE, which indicates that IPE is well-tolerated. |
|---|
| ジャーナル名 | Expert opinion on drug safety |
|---|
| Pubmed追加日 | 2023/10/24 |
|---|
| 投稿者 | Cai, Haixia; Jia, Beixi; Fu, Zhonghua; Chen, Boya; Liu, Yinping; Zhao, Shujuan |
|---|
| 組織名 | Department of Pharmacy, Henan Provincial People's Hospital, Zhengzhou, China.;Department of Pharmacognosy, School of Pharmaceutical Science, Zhengzhou;University, Zhengzhou, China. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/37873598/ |
|---|
